摘要
目的 探讨布地奈德联合异丙托溴铵雾化给药在支气管哮喘急性发作期患者中应用对肺功能、症状缓解和生活质量的影响.方法 于我院2015年6月~2019年2月选取500例支气管哮喘急性发作期需治疗患者,并从中选取136例按入院顺序分为观察组和对照组,每组68例.所有患者予以常规治疗,对照组在此基础上予以沙丁胺醇治疗,观察组在对照组基础上予以布地奈德联合异丙托溴铵雾化治疗,疗程均为2周.比较两组治疗后肺功能、症状缓解时间,同时比较治疗前及治疗3个月后的生活质量评分.结果 两组治疗前峰值呼气流速(PEF)、第1秒用力呼气容积预计值百分比(FEV1%)、FEV1与用力肺活量比值(FEV1/FVC)水平以及生活质量评分(SGRQ)相持平,差异无统计学意义(P>0.05);观察组治疗后PEF、FEV1%和FEV1/FVC值分别为(66.92±7.11)L/min、(74.29±4.18)%和(69.12±5.31)%,均高于治疗前和对照组;观察组治疗后3个月的生活质量评分(SGRQ)为(36.29±12.11)分,均低于治疗前和对照组;治疗后咳嗽缓解时间、胸闷缓解时间、气急缓解时间和哮鸣音缓解时间分别为(3.80±1.12)d、(2.19±0.37)d、(2.69±0.43)d和(4.38±1.07)d,均少于对照组,差异均有统计学意义(P<0.05).结论 ?布地奈德联合异丙托溴铵雾化治疗支气管哮喘急性发作期患者临床效果明显,可有效改善肺功能,缓解咳嗽、气急、胸闷等临床症状,提高生活质量,值得临床推广应用.
Objective To investigate the effects of atomized administration of budesonide combined with ipratropium bromide on pulmonary function,symptom relief,and quality of life in patients with acute attack of bronchial asthma.Methods 500 patients requiring treatment for acute attack of bronchial asthma at our hospital from June 2015 to February 2019 were selected,and 136 patients were selected according to the order of admission and divided into the observation group and the control group,with 68 patients in each group.All patients were given conventional therapy.The control group was treated with salbutamol on this basis,while the observation group was treated with atomization of budesonide combined with ipratropium bromide on the basis of the control group.The course of treatment was 2 weeks.Pulmonary function and symptom remission time after treatment were compared between the two groups.Meanwhile,the quality of life scores were compared before treatment and after 3 months of treatment.Results Before treatment,the levels of peak expiratory flow(PEF),forced expiratory volume in one second percentage of expected value(FEV1%),and ratio of FEV1 to forced vital capacity(FEV1/FVC),and the quality of life score(SGRQ)of the two groups were the same,with no statistically significant difference(P>0.05);After treatment,the values of PEF,FEV1%and FEV1/FVC in the observation group were(66.92±7.11)L/min,(74.29±4.18)%and(69.12±5.31)%,respectively,which were all higher than those before treatment and in the control group;The quality of life score(SGRQ)in the observation group at 3 months after treatment was(36.29±12.11)points,which was lower than that before treatment and in the control group;After treatment,the remission time of cough,chest tightness,shortness of breath,and wheezes were(3.80±1.12)d,(2.19±0.37)d,(2.69±0.43)d and(4.38±1.07)d,respectively,which were all less than that in the control group.The above differences were all statistically significant(P<0.05).Conclusion Atomization of budesonide combined with ipratropium bromide in the treatment of patients with acute attack of bronchial asthma has obvious clinical effect,which can effectively improve pulmonary function,relieve cough,shortness of breath,chest tightness and other clinical symptoms,and improve the quality of life,which is recommended for clinical promotion and application.
作者
陈英吉
程明康
刘贤广
CHEN Yingji;CHENG Mingkang;LIU Xian'guang(Department of Respiratory Medicine,Songyuan Jilin Oilfield Hospital,Jilin,Songyuan 138000,China;Department of Thoracic Surgery,Songyuan Jilin Oilfield Hospital,Jilin,Songyuan 138000,China)
出处
《中国医药科学》
2020年第6期53-55,72,共4页
China Medicine And Pharmacy
关键词
布地奈德
异丙托溴铵
支气管哮喘急性发作
肺功能
临床症状
生活质量
Budesonide
Ipratropium bromide
Acute attack of bronchial asthma
Pulmonary function
Clinical symptoms
Quality of life
